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Abstract
Background: Screening is the main preventive method for cervical cancer in developing countries, but each type
of screening has advantages and disadvantages. To investigate the most suitable method for low-income areas in
China, we conducted a health economic analysis comparing three methods: visual inspection with acetic acid and
Lugol’s iodine (VIA/VILI), ThinPrep cytology test (TCT), and human papillomavirus (HPV) test.
Methods: We recruited 3086 women aged 35–65 years using cluster random sampling. Each participant was randomly
assigned to one of three cervical cancer screening groups: VIA/VILI, TCT, or HPV test. In order to calculate the number
of disability-adjusted life years (DALYs) averted by each screening method, we used Markov models to estimate the
natural development of cervical cancer over a 15-year period to estimate the age of onset and duration of each
disease stage. The cost-effectiveness ratios (CERs), net present values (NPVs), benefit-cost ratios (BCRs), and cost-utility
ratios (CURs) were used as outcomes in the health economic analysis.
Results: The positive detection rate in the VIA/VILI group was 1.39%, which was 4.6 and 2.0 times higher than the
rates in the TCT and HPV test groups, respectively. The positive predictive value of VIA/VILI (10.53%) was highest
while the rate of referral for colposcopy was lowest for those in the HPV + TCT group (0.60%). VIA/VILI performed
the best in terms of health economic evaluation results, as the cost of per positive case detected was 8467.9 RMB,
which was 24503.0 RMB lower than that for TCT and 5755.9 RMB lower than that for the HPV test. In addition, the
NPV and BCR values were 258011.5 RMB and 3.18 (the highest), and the CUR was 2341.8 RMB (the lowest). The TCT
performed the worst, since its NPV was <0 and the BCR was <1, indicative of being poorly cost-beneficial.
Conclusions: With the best economic evaluation results and requiring minimum medical resources, VIA/VILI is
recommended for cervical cancer screening in poverty-stricken areas in China with high incidence of cervical
cancer and lack of medical resources.
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Background
Cervical cancer is the third most common malignancy
in women worldwide, with an estimated 528,000 new
cases and 266,000 deaths in 2012 (approximately 85%
of the global burden was from less developed countries)
[1, 2]. Generally, cervical cancer incidence and mortality
rates are highest in Eastern and Middle Africa [2]. Al-
though the rates in China are better, there were still
62,000 new cases of cervical cancer in 2012; this is
about five times greater than in the United States [2].
The incidence of cervical cancer in Wufeng County, a
typical rural areas in China, is high (58.14 per 100,000),
with a mortality rate of 22.43 per 100,000 in 2012, far
above the Chinese average. More research is needed to
effectively reduce the incidence of cervical cancer in
the rural areas of China.
About 70% of cervical cancer cases are associated with
human papillomavirus (HPV)-16, 18 [3]. This provides a
new target for prevention. Since the first HPV vaccine
was approved for use by the US Food and Drug Admin-
istration (FDA) in 2006, vaccination is rapidly becoming
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one of the main means of cervical cancer prevention
[4]. However, HPV vaccines are not used worldwide. In
fact, only six low-income countries have included HPV
vaccination in their national immunization programs
[5]. There are only three kinds HPV vaccines; these
currently target subtypes 6/11/16/18/31/33/45/52/58,
whereas HPV has up to 148 recognized subtypes [6–8].
HPV vaccine is recommended for girls aged 13–26 who
have not been vaccinated [9, 10]. However, the World
Health Organization (WHO) emphasizes that HPV vac-
cination should not replace cervical cancer screening,
especially for those older than 26 years [11]. Therefore,
screening remains essential for cervical cancer preven-
tion globally, especially in developing countries.
Cervical cancer screening is more common than HPV
vaccination in China. Since 2009, free cervical screen-
ing has been provided in some rural areas for women
aged 35–59 years. However, in the first three years of
the project, the coverage of women in rural areas was
less than 2% [12]. Therefore, more efficient screening
methods are needed. Three kinds of cervical screening
methods (cytology, HPV test, and visual inspection with
acetic acid [VIA/VILI] or with Lugol’s iodine [VILI])
are currently widely used [13]. Each of them has its
advantages and disadvantages. In terms of cytology, the
specificity of the traditional Pap smear in detecting cer-
vical intraepithelial neoplasia (CIN) 2+ is high (96.3%),
but sensitivity is low (53.0%); whereas the ThinPrep cy-
tologic test (TCT) is more sensitive, but has the lowest
specificity of all the screening methods. The sensitivity
(96.1%) and specificity (90.7%) of the HPV test are sat-
isfactory; however, it is a more difficult test to promote
in low income areas because it requires more medical
resources and is more costly (as is the TCT). The speci-
ficity (92%) and sensitivity (80%) of VIA are moderate,
but it has a high false-positive rate and is highly sub-
jective [14–16]. The screening organizer should take
into account the applicability of each screening method,
since the cost and outcome of the each will affect its
use in specific places.
According to the WHO, less costly cervical cancer
screening methods are more applicable in low income
areas, when assessing cost only; not the combination of
screening costs and outcomes [17]. In the present study,
we conducted a health economic analysis to evaluate
each cervical screening method in terms of combination
of cost and outcome, to determine the most suitable
screening method for poor rural areas in China where
the incidence of cervical cancer is high.
Method
This study was conducted in three parts: (1) three cer-
vical cancer screening methods were applied to deter-
mine the costs and the positive cases in each step. (2) a
Markov model was developed to estimate the natural de-
velopment of cervical cancer for 15 years for the positive
cases detected by screening. (3) a health economic ana-
lysis that included costing analysis, effectiveness/benefit/
utility analysis, and cost-effectiveness/cost-benefit/cost-
utility analysis was conducted, from the perspective of the
user. In the study, the medical costs of screening were col-
lected during screening. The unit costs of medical treat-
ment were obtained from local the Maternal and Child
Health Care Hospital. The daily social costs per person
were obtained from the local “Statistical Yearbook (2014)”.
Cervical cancer screening
Cluster random sampling was used to recruit 3086 women
aged 35–65 years, as recommended by WHO and the
Cancer Foundation of China (CFC) [18, 19]. Each sub-
ject was randomly assigned to one of three cervical can-
cer screening groups: VIA/VILI, TCT, or HPV test. Each
screening method was performed according to the
WHO’s “Comprehensive Cervical Cancer Control: A
guide to essential practice (2nd edition)”. Cervical cancer
was graded according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system (2009
version), and pathologic results were classified by the
cervical precancerous lesions classification system re-
leased by the WHO in 2014. Women confirmed to be
positive received appropriate treatment (surgery for ≥
CIN2, and follow-up for CIN1).
Markov model application
We used TreeAge Pro 2011 software (TreeAge Software,
Inc., Williamstown, MA, USA) to develop a Markov
model to estimate the natural development of cervical
cancer for 15 years (it takes approximately 10 years for
precancerous cervical lesions to progress to cervical
cancer, and death from cervical cancer is commonly
expressed as a 5-year survival rate [19]). From this we
estimated the age of onset and duration of each disease
stage, in order to calculate the disability-adjusted life-
years (DALYs) of each group. Seven Markov states were
set up; the mutual transition of each Markov state is
shown in Fig. 1.
Patients transitioned between the Markov states
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Each column or row of the matrix represents a Markov
state, and the numbers in each row are transition prob-
abilities. More specifically, the first row is the transition
probability that the state “UNTESTED” transfers to each
other state (“UNTESTED”, “HPV”, “CIN 1”, “CIN 2”,
“CIN 3”, “CANCER”, and “DEAD”) within a year. The
second is the transition probability that the state “HPV”
transfers to each other state, etc. After each annual cycle,
patients either transitioned to a different Markov state or
remained in the same state. We assumed that the state
would stop processing after 15 years. To determine the
number of patients in each state in the subsequent year,
we multiplied the number of patient in each state by the
corresponding transition probability. For example, the
number of patients in the state “UNTESTED” multiplied
by the probability in the first row gives the number of
people in each state in the next year who transitioned
from the state “UNTESTED”.
Data analysis
Costing analysis
Cost can be divided into medical cost (medical resource
consumption) and social cost (food, accommodation,
transportation, communication and workforce product-
ivity loss). The direct treatment cost of precancerous
lesions and cervical cancer were specified by govern-
ment (2400.0 RMB for CIN 2, 5650.0 RMB for CIN 3
and 8500.0 RMB for cancer). The radiotherapy and
chemotherapy costs (54823.3 RMB) of cervical cancer
were cited from relevant research [23]. Hospitalization
data were provided by the local hospital. We averaged
the hospital length of stay for the period 2011–2015,
obtaining an average duration of hospitalization of
5.8 days for CIN 1, 7.5 days for CIN 2, 12.3 days for
CIN 3, and 26.3 days for Cancer. From the social per-
spective, we obtained the daily per capita costs of diet
(8.5 RMB), accommodation (3.7 RMB), transportation
and communication (2.8 RMB), and wage (93.8 RMB)
from the local “Statistical Yearbook (2014)”. Costs be-
yond the study duration were discounted at 3% per
year. We multiplied the daily costs by the time spent
on screening or hospitalization to calculate the social
costs of screening and treatment.
Effectiveness, benefit and utility analysis
We used the positive detection rate, positive predictive
value, and rate of referral for colposcopy as outcomes in
the effectiveness analysis. The cost difference between
the early-treated group and non-early treated group was
calculated as the outcome in the benefit analysis. DALYs
lost due to cervical cancer were used as the outcome in
the utility analysis. The DALYs were calculated as the
sum of the Years of Life Lost (YLL) due to premature
death and the Years Lost due to Disability (YLD) for
people living with the health condition or its conse-
quences [24]. We calculated these using following
equation derived by Murray [25, 26]:
YLL YLDð Þ ¼
−
DCe−βα
βþ γð Þ2 e
− βþγð ÞL 1þ βþ γð Þ Lþ αð Þ½ − 1þ βþ γð Þα½ 
n o
where D is the disability weight; γ (valued at 0.03) is the
social discount rate; α is the age of the individual at the
onset of symptoms; L is the duration of the disability or
premature mortality; C (valued at 0.1658) is the age-
weighting correction constant; and β (valued at 0.04) is
the parameter from the age-weighting function.
The duration of the disability or premature death was
derived from the results of Markov model simulation.
The disability weight for precancerous lesions and
cervical cancer were as follows: 0 for state less than
“CIN 1”, 0.1238 for “CIN 2”, 0.1941 for “CIN 3”, 0.307
for “CANCER”, and 1for “DEAD” [27]. We used the
model life table West level 26 for the standard life ex-
pectancy of women.
Economic analysis
We evaluated the cost-effectiveness of each screening
method with cost effectiveness ratio (CER=cost/the
Fig. 1 Mutual transition of the seven Markov states in the natural development of cervical cancer. A Markov cycle (one year) of mutual transition
is described in the figure. The squares represent the seven different Markov health states. The arrows represent the direction of transition.
The Markov state “CANCER” and “DEAD” cannot reverse transfer, and “DEAD” is the absorbing state, it cannot transfer to other states. HPV:
HPV infection
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number of positive patients) which was the cost of per
positive patient been screened out. The net benefit
value (NPV= benefit-cost), and benefit cost ratio
(BCR= benefit/cost) were calculated in the cost-benefit
analysis. Screening methods with a NPV>0 and BCR>1
were considered cost-beneficial. The cost utility ratio
(CUR=cost/DALYs), that indicate the cost per DALY
averted, was calculated in the cost-utility analysis.
Sensitivity analysis
Given the uncertainty about some parameters (radio-
therapy and chemotherapy costs, discount rate) that
were not collected during the study, univariate sensi-
tivity analyses were used to assess the robustness of
the health economic evaluation results. The variation
in the range of radiotherapy and chemotherapy costs
was ±5% and ±10% of the original value. The value of
the discount rate changed by ±1% and ±2%.
Results
Cervical cancer screening results
The detailed implementation procedure of cervical cancer
screening is presented in Fig. 2. Fourteen positive cases
were confirmed in the VIA/VILI group (8 had CIN 1, 3
had CIN 2, and 3 had CIN 3), three positive cases were
confirmed in the TCT group (2 had CIN 1, and 1 had
CIN3), and seven positive cases were confirmed in the
HPV test group (2 had CIN 1, 1 had CIN 2, 3 had CIN3,
and 1 had Cancer). The data of some subjects who were
positive in the initial screening were missing from the re-
examination of each group (2 from the VIA/VILI group,
12 from the TCT group, and 13 from the HPV test group).
Health economic evaluation
Costing analysis
Screening costs: The total screening cost per capita was
highest for VIA/VILI, followed by the HPV test (Table 1).
Fig. 2 Cervical cancer screening procedure. Numbers in brackets denote the number of the procedure. Subjects identified as positive on initial
HPV test screening were assigned to one of three re-examination groups (direct to Colposcopy, Cytology or VIA/VILI). Subjects who were positive
in the initial VIA/VILI or TCT screening were re-examined directly by colposcopy. Endocervical curettage (ECC) was performed if colposcopy was
inadequate or unsatisfactory
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However, the per capita initial screening costs of the
three screening method were the opposite. This was due
to the diagnosis confirmation costs, that were as high as
37367.5 RMB in the VIA/VILI group, 3.48 times that of
TCT group and 2.34 times that of HPV test group. In
total, the screening costs of the VIA/VILI group were
highest (118550.6 RMB), and were 19338.0 RMB and
18983.8 RMB higher than those of the TCT group and
the HPV group, respectively.
Treatment costs: the direct medical costs accounted
for the largest share of treatment costs, followed by in-
direct costs (Table 2). Thus, medical resource consump-
tion was the main source of economic burden, with only
a small portion of treatment cost accounted for by social
costs. The early-treatment cost was highest for the HPV
test group (97598.1 RMB). The non-early treatment cost
was highest for the VIA/VILI group (413251.4 RMB);
this cost was 1.20 times that of the HPV test group. The
total treatment cost of the TCT group (68875.3 RMB)
was the lowest.
Effectiveness, benefit and utility analysis
Simulation results of Markov model: according to the
simulation results of natural development of cervical
cancer for 15 years, VIA/VILI averted the greatest
number of YLD every year, followed by the HPV test
(Fig. 3). However, the YLL averted by these two
methods was opposite. The TCT had the fewest YLD
and YLL averted. The YLD averted by the three screen-
ing methods generally decreased over time, while the
YLL increased over time.
Effectiveness: both the positive detection rate (1.39%)
and the positive predictive value (10.53%) were higher in
the VIA/VILI group than in the other two groups
(Table 3). The rate of referral for colposcopy in the HPV
test + TCT group (0.60%) was lowest, and HPV test +
VILI (1.80%) was second. Benefit: the economic benefits
brought by the VIA/VILI were 376562.1 RMB, much
higher than the other two. Utility: The DALYs averted
by VIA/VILI (50.624), was the highest of all the groups.
Economic analysis
The value of a screening program is influenced by both
input and output. Although the per capita costs of VIA/
VILI were highest, the cost-effectiveness (8467.9 RMB
Table 1 Screening costs for the three screening groups
Cost components VIA/VILI TCT HPV Test
Propaganda costs 51562.4 (51.2) 51562.4 (51.0) 51562.4 (51.5)
Initial screening costs
Labor costs of drawing materials 12399.6 (12.3) 4145.1 (4.1) 4100.0 (4.1)
Consumable costs of drawing materials 5284.1 (5.2) 5088.2 (5.0) 5032.9 (5.0)
Instrument costs of drawing materials 446.4 (0.4) 448.2 (0.4) 443.3 (0.4)
Reading costs of TCT – 23048.4 (22.8) –
Detection costs of HPV test – – 13238.9 (13.2)
Costs of workforce productivity losses 5252.8 (5.2) 2157.4 (2.1) 2063.6 (2.1)
Confirmed diagnosis costs
Colposcopy cost 13459.6 (101.2) 4352.9 (101.2) 5363.6 (101.2)
Costs of pathological examination 23908.0 (278.0) 6393.3 (278.0) 8062.0 (278.0)
VIA/VILI cost – – 877.1 (17.9)
TCT cost – – 1647.3 (32.3)
Costs of workforce productivity losses 6237.7 (46.9) 2016.7 (46.9) 7175.7 (46.9)
Total 118550.6 (117.6) 99212.6 (98.0) 99566.8 (99.5)
Data in the table represent the total cost (numbers outside parentheses) and per capita cost (numbers within parentheses). The unit for all values is RMB
Table 2 Treatment costs for the three screening groups
Cost (RMB) VIA/VILI TCT HPV test
Early-treatment cost
Direct medical cost 24150.0 5650.0 82673.3
Direct non-medical cost 1395.9 289.1 1661.5
Indirect cost 11143.4 2307.5 13263.3
Total 36689.3 8246.6 97598.1
Non-early treatment cost
Direct medical cost 379939.8 63323.3 316616.5
Direct non-medical cost 3708.3 618.1 3090.3
Indirect cost 29603.3 4933.9 24669.4
Total 413251.4 68875.3 344376.2
Direct medical cost refers to the cost of medical resource consumption. Direct
non-medical cost refers to the cost of diet, accommodation, transportation
and communication. Indirect cost refers to the cost of workforce productivity
losses. The non-early treatment cost was the cost of cervical cancer treatment
for patients who were screened to be ≥ CIN2 (we assumed these patients did
not receive intervention, and they developed a cervical cancer)
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per person for CER), cost-benefit (258011.5 RMB for NPV
and 3.18 for BCR), and cost-utility (2341.8 RMB per
DALY averted for CUR) of VIA/VILI were all optimal
(Table 3). In terms of the cost-utility analysis, there was
little difference between the HPV test group and the VIA/
VILI group, but the results of the cost-effectiveness ana-
lysis and cost-benefit analysis were markedly different.
TCT had the worst results in the economic analysis with a
NPV <0 and a BCR <1, which indicate a poor cost-benefit.
Sensitivity analysis (Fig. 4)
When the variation range of radiotherapy and chemother-
apy costs were ±5 and ±10% of the original value, the CER
and CUR of three groups were unaffected, indicating good
stability. However, the NPVs and BCRs were influenced
greatly, such that the maximum range of variation of NPV
was up to ±14.9% of the original value, and the maximum
range of variation of BCR was up to ±9.24% of the original
value. When the value of the discount rate changed ±1%
and ±2%, the results of economic evaluation were very
stable; the maximum variation range was only 0.19%. In
all, the results of the comparison of the three screening
groups for economic evaluation did not change,
irrespective of the cost of radiotherapy or chemotherapy.
Similarly, whether the discount rate changed or not, the
CER, NPV, BCR, and CUR values of VIA/VILI were still
the best of the three groups.
Discussion
The economic burden of HPV vaccination in rural areas
is unaffordable; cervical cancer screening is still the
primary preventive measure for cervical cancer. Our
findings show that the per capita treatment cost of cer-
vical cancer was 63323.3 RMB. However, the annual net
income per capita was 8895.9 RMB in rural areas of
China, with only 2270.4 RMB of disposable income
when excluding life consumer spending [28]. Despite the
Chinese government’s establishment of the New Rural
Cooperative Medical System for treatment of serious
illnesses in patients in rural areas, under which up to
70% of the cost of hospitalization for cervical cancer is
reimbursed, the economic burden of the remaining costs
of cervical cancer treatment (18997.0 RMB) for rural
women has reached 213.6% [29]. Although both HPV
vaccination and cervical cancer screening are ways to
prevent cervical cancer, the economic burden of a single
Fig. 3 Simulation results of YLD and YLL averted by 3 screening methods with Markov model. Given the assumption that the state would not
progress after 15 years, the DALYs averted in each group 14 years later were calculated in total. Thus, only the results for 14 years are shown. The
YLD and YLL averted by each screening method 14 years later were 9.796, and 22.167 for VIA/VILI, 3.336, and 8.612 for TCT and 4.647, and 17.821
for the HPV test
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dose of HPV vaccine is 7.12% (63.3 RMB), while the
maximum economic burden of cervical cancer screening
(not including the cost of educational material/advertis-
ing) is 0.75% (66.4 RMB) [30].
The averted DALYs of each patient in this study were
calculated more specifically, as a combination of the
Markov model and calculation formula of DALYs,
derived by Murray, was performed. This was weighted
by age, and different stages of the disease were included
in the calculation. As far as we know, this is the first
time these two methods for calculating DALYs have
been used in combination in cervical cancer research.
A search for previous studies on cervical cancer in the
PubMed database identified only three studies with
similar detailed handling (such as age-weighting and in-
cluding different disease stages) of DALY calculation.
Only two were related to health economic evaluation,
and none combined the Markov model with the DALY
calculation formula derived by Murray [31–33].
The cost-utilities of VIA/VILI, TCT, and the HPV test,
especially for VIA/VILI, were very effective in the study,
since the CURs were lower than China’s GDP per capita
(GDP per capita = 49886.8 RMB in 2014, according to
the World Bank [34]). However, this result is based on a
high participation rate in cervical cancer screening
programs. The participation rate in this study was 97.9%,
whereas studies on cervical cancer screening in rural
areas of China in recent years have shown a participa-
tion rate of approximately 24% [28, 35]. Even in rural
areas where cervical cancer screening is free of charge,
the participation rate in VIA/VILI screening programs
can be as low as 35% [35]. Thus, improvement of partici-
pation rates among women in rural areas is necessary
before implementation of cervical cancer screening.
The VIA/VILI is more suitable for cervical cancer pre-
vention in the rural areas that lack medical resources
and a high incidence of cervical cancer than TCT or
HPV test; it showed the best economic evaluation results
and requires minimal medical resources. Consistent with
this finding, the WHO proposed that VIA/VILI should
be the first choice for areas with a shortage of medical
resources [17]. Despite the advantages of VIA/VILI, its
sensitivity and specificity are vulnerable to the subjective
understanding and clinical experience of screening
operators. The specificity of VIA/VILI can be as high as
90% if screening operators have been professionally
trained [36]. Therefore, more attention should be paid
to the training of operators performing cervical cancer
screening.
There are some limitations to this study. First, because
of the limited medical resources in the study area, hospi-
tals lacked outpatient medical record systems, making it
difficult to collect clinical data. Second, only the expenses
of hospitalization were included in direct medical treat-
ment costs. Last, since the use of several joint screening
methods has been proposed, the use of the three cervical
cancer screening methods independently in the study
could be a limitation.
Conclusion
VIA/VILI is recommended for cervical cancer screening
in rural areas with a high incidence of cervical cancer. It
is a more effective method of reducing the burden of
cervical cancer considering the local economic level and
requires less medical equipment and personnel than the
other two screening methods. Future studies on health
economic evaluation of cervical cancer screening in rural
areas should take clinic data into account or focus on
combined screening.
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